Lessons Learned From Limited Overlap of 15 In Vitro COVID-19 Drug Repurposing Screens-Reference-Cited by-同舟云学术

Lessons Learned From Limited Overlap of 15 In Vitro COVID-19 Drug Repurposing Screens

Published:2023-08-01 Issue:4 Volume:21 Page:249-257
ISSN:2326-5094
Container-title:Health Security
language:en
Short-container-title:Health Security

Author:

Tomezsko Phillip J.¹,Phillipson Cassandra W.²,Walsh Matthew E.³⁴

Affiliation:

1. Phillip J. Tomezsko, PhD, is Technical Staff, Counter WMD Systems Group, MIT Lincoln Laboratory, Lexington, MA.

2. Casandra W. Philipson, PhD, was Technical Staff, MIT Lincoln Laboratory, Lexington, MA.

3. Matthew E. Walsh was Associate Technical Staff, Biological and Chemical Technologies Group, MIT Lincoln Laboratory, Lexington, MA.

4. Matthew E. Walsh is currently a PhD Student, Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

Publisher

Mary Ann Liebert Inc

Subject

Health, Toxicology and Mutagenesis,Management, Monitoring, Policy and Law,Public Health, Environmental and Occupational Health,Safety Research,Emergency Medicine,Health (social science)

Link

https://www.liebertpub.com/doi/pdf/10.1089/hs.2022.0132

Reference16 articles.

1. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018

2. Drug repurposing: progress, challenges and recommendations

3. What Are the Odds of Finding a COVID-19 Drug from a Lab Repurposing Screen?

4. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions

5. Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Introduction to the Global Catastrophic Biological Risks Special Feature;Health Security;2023-08-01